PMV Pharmaceuticals reports news as a precision oncology company developing small molecule therapies that target p53. Its recurring updates center on rezatapopt, an oral product candidate designed to reactivate mutant p53 in tumors with the TP53 Y220C mutation, and on the PYNNACLE clinical trial in advanced solid tumors, including ovarian cancer.
Company announcements also cover clinical data presentations and publications, FDA designation activity, periodic financial results, research and development spending tied to rezatapopt, cash runway commentary, and board governance changes.
PMV Pharmaceuticals (PMVP) appointed Matt Eckler, Ph.D., to its Board of Directors as it prepares a regulatory application for rezatapopt. Eckler is a Principal at Samsara BioCapital and brings more than two decades of combined healthcare investing and scientific research experience.
Enrollment is complete in the Phase 2 monotherapy portion of the ongoing PYNNACLE pivotal trial. The company plans to submit a New Drug Application seeking accelerated approval in the first quarter of 2027 for rezatapopt in patients with platinum-resistant/refractory ovarian cancer with a TP53 Y220C mutation. Rezatapopt has FDA Fast Track designation for locally advanced or metastatic solid tumors with a p53 Y220C mutation and Orphan Drug Designation for TP53 Y220C positive ovarian, fallopian tube and primary peritoneal cancers.
PMV Pharma (Nasdaq: PMVP) priced an oversubscribed underwritten public offering totaling approximately $50.8 million in gross proceeds. The deal includes 22,055,000 shares of common stock, pre-funded warrants to purchase up to 19,900,000 shares, and accompanying warrants to purchase an aggregate of 41,955,000 shares.
Each share of common stock plus accompanying warrant is priced at $1.21, while each pre-funded warrant plus accompanying warrant is priced at $1.20999. The accompanying warrants are immediately exercisable at an initial exercise price of $1.21 per share, subject to adjustment after a specified regulatory milestone, and will expire five years from issuance. All securities are being sold by PMV Pharma, with TD Cowen as sole book-running manager. Closing is expected on or about September 2, 2026, subject to customary conditions.
PMV Pharma (Nasdaq: PMVP) has commenced an underwritten public offering of its common stock with accompanying warrants, and pre-funded warrants with accompanying warrants for certain investors. All securities in the proposed offering will be sold by PMV Pharma. TD Cowen is the sole book-running manager, and the transaction is being conducted under an effective shelf registration statement on Form S-3. Completion, timing, size and final terms of the offering remain subject to market and other conditions.
PMV Pharmaceuticals (Nasdaq: PMVP) reported updated interim ovarian cancer data from the Phase 2 pivotal portion of its PYNNACLE trial of rezatapopt monotherapy (2000 mg once-daily) in patients with TP53 Y220C advanced solid tumors. As of the May 14, 2026 cutoff, the efficacy population included 76 platinum-resistant/refractory ovarian cancer patients with at least one post-baseline tumor assessment or early discontinuation.
According to PMV Pharma, the ovarian cancer cohort showed an overall response rate (ORR) of 46% (35/76), including four confirmed complete responses, 29 confirmed partial responses, and two unconfirmed partial responses, per investigator RECIST v1.1 assessment. Median time to response was 1.3 months, and median duration of response was 10.0 months based on confirmed responses. Rezatapopt’s safety profile remained favorable, with mostly Grade 1–2 treatment-related adverse events and a 5% discontinuation rate due to treatment-related adverse events; safety in the ovarian cohort was similar to the overall population. PMV Pharma completed enrollment of the ovarian cancer cohort for the primary analysis and plans a broader PYNNACLE update, including primary analysis data, at a medical conference in fourth-quarter 2026. Following recent FDA feedback supporting its strategy, the company anticipates submitting a New Drug Application for accelerated approval in platinum-resistant/refractory TP53 Y220C ovarian cancer in the first quarter of 2027.
PMV Pharmaceuticals (Nasdaq: PMVP) reported second quarter 2026 results and clinical progress for rezatapopt. Enrollment for the primary analysis in the Phase 2 monotherapy portion of the registrational PYNNACLE trial in platinum-resistant/refractory ovarian cancer has been completed. The company plans to submit a rezatapopt NDA for accelerated approval in this indication in the first quarter of 2027.
PMV Pharma reported $79.4 million in cash, cash equivalents and marketable securities as of June 30, 2026, and expects this to fund operations through the second quarter of 2027. Net loss for the quarter was $18.1 million, down from $21.2 million a year earlier, with R&D expenses reduced to $14.7 million from $18.4 million and G&A expenses down to $4.2 million from $4.5 million. Net cash used in operations for the first half of 2026 was $34.3 million versus $36.6 million in the prior-year period.
PMV Pharma (Nasdaq: PMVP) reported Q1 2026 results and rezatapopt milestones. Rezatapopt received FDA Orphan Drug Designation for TP53 Y220C positive ovarian, fallopian tube, and primary peritoneal cancers, and Phase 1 data were published in the New England Journal of Medicine.
Phase 2 PYNNACLE monotherapy showed a 44–46% ORR in platinum-resistant/refractory ovarian cancer. An NDA submission is planned for Q1 2027. Cash, cash equivalents, and marketable securities were $93.5 million, providing expected runway to end of Q2 2027; Q1 net loss was $18.0 million.
PMV Pharma (Nasdaq: PMVP) announced a Board leadership change: Laurie Stelzer will become Board Chair effective at the 2026 Annual Meeting on June 4, 2026, succeeding Rich Heyman, Ph.D., who will retire and not stand for reelection.
The Company says enrollment continues in the registrational PYNNACLE trial for rezatapopt in TP53 Y220C advanced solid tumors, with an anticipated NDA submission in Q1 2027 for platinum-resistant/refractory ovarian cancer patients with the TP53 Y220C mutation.
PMV Pharmaceuticals (Nasdaq: PMVP) reported full-year 2025 results and clinical progress for rezatapopt. Key clinical highlights include FDA Orphan Drug Designation (Mar 2, 2026), NEJM publication of Phase 1 data, Phase 2 PYNNACLE activity with ovarian cohort ORRs up to 50% post-cutoff, and an NDA planned for Q1 2027. Financials: $112.9M cash and marketable securities as of Dec 31, 2025, net loss of $77.7M, and net cash used in operations of $73.6M, providing runway to end of Q2 2027.
PMV Pharma (Nasdaq: PMVP) reported that Phase 1, first-in-human rezatapopt data were published in the New England Journal of Medicine on Feb 26, 2026. The Phase 1 portion enrolled 77 heavily pretreated TP53 Y220C-mutant patients, showed objective responses across tumor types, supported an RP2D, and demonstrated safety, pharmacokinetics, and biomarker evidence of selective Y220C p53 reactivation. The company plans a New Drug Application submission in Q1 2027 for platinum-resistant/refractory ovarian cancer and reported Phase 2 interim ORR of 34% overall and 46% in ovarian cancer (data cutoff Sep 4, 2025).
PMV Pharmaceuticals (Nasdaq: PMVP) reported third-quarter 2025 results and clinical updates on rezatapopt from the Phase 2 pivotal PYNNACLE study presented at the 2025 AACR-NCI-EORTC conference on October 24, 2025.
Key clinical data: 34% ORR (35/103) across evaluable patients, 46% ORR in the ovarian cohort (22/48) with one confirmed complete response and median duration of response of 8.0 months in ovarian patients. Median time to response across cohorts was 1.3 months. The company plans an NDA submission for platinum-resistant/refractory ovarian cancer in Q1 2027.
Financials: cash, equivalents, and marketable securities of $129.3M as of September 30, 2025, providing expected runway to end of Q1 2027. Net cash used in operations was $56.4M for the nine months ended September 30, 2025.